[{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IAM1363","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Iambic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule, Immediate Release","sponsorNew":"Iambic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Iambic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Mubadala Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"IAM1363","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Iambic Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Capsule, Immediate Release","sponsorNew":"Iambic Therapeutics \/ Mubadala Capital","highestDevelopmentStatusID":"6","companyTruncated":"Iambic Therapeutics \/ Mubadala Capital"},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"IAM1363","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Iambic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule, Immediate Release","sponsorNew":"Iambic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Iambic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"IAM-H1","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Iambic Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Iambic Therapeutics \/ Ascenta Capital","highestDevelopmentStatusID":"5","companyTruncated":"Iambic Therapeutics \/ Ascenta Capital"},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Iambic Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Iambic Therapeutics \/ Revolution Medicines","highestDevelopmentStatusID":"3","companyTruncated":"Iambic Therapeutics \/ Revolution Medicines"},{"orgOrder":0,"company":"Iambic Therapeutics","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"IAM1363","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Iambic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule, Immediate Release","sponsorNew":"Iambic Therapeutics \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Iambic Therapeutics \/ Jazz Pharmaceuticals"}]